Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) —
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
Altamira’s two flagship programs, AM-401 and AM-411, designed for KRAS-driven cancer and rheumatoid arthritis, serve to demonstrate the technology’s capability to enhance therapeutic efficacy
Related news for (CYTO)
- Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
- Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
- altamira therapeutics provides update on nasdaq listing
- altamira therapeutics announces extended iso 13485 quality management system certification for bentrio nasal spray
- altamira therapeutics provides business update and first half 2024 financial results